Hernández-Alcoceba R - Search Results

1

LUMO energy of model compounds of bispyridinium compounds as an index for the inhibition of choline kinase.

Campos J, del Carmen Núñez M, Rodríguez V, Entrena A, Hernández-Alcoceba R, Fernández F, Lacal JC, Gallo MA, Espinosa A. Campos J, et al. Eur J Med Chem. 2001 Mar;36(3):215-25. doi: 10.1016/s0223-5234(01)01219-3. Eur J Med Chem. 2001. PMID: 11337100

2

QSAR-derived choline kinase inhibitors: how rational can antiproliferative drug design be?

Campos J, Núñez MC, Conejo-García A, Sánchez-Martín RM, Hernández-Alcoceba R, Rodríguez-González A, Lacal JC, Gallo MA, Espinosa A. Campos J, et al. Curr Med Chem. 2003 Jul;10(13):1095-112. doi: 10.2174/0929867033457539. Curr Med Chem. 2003. PMID: 12678804 Review.

3

Choline kinase inhibitors as a novel approach for antiproliferative drug design.

Hernández-Alcoceba R, Saniger L, Campos J, Núñez MC, Khaless F, Gallo MA, Espinosa A, Lacal JC. Hernández-Alcoceba R, et al. Oncogene. 1997 Nov 6;15(19):2289-301. doi: 10.1038/sj.onc.1201414. Oncogene. 1997. PMID: 9393874

4

In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery.

Hernández-Alcoceba R, Fernández F, Lacal JC. Hernández-Alcoceba R, et al. Cancer Res. 1999 Jul 1;59(13):3112-8. Cancer Res. 1999. PMID: 10397253

5

Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity.

Lucas L, Hernández-Alcoceba R, Penalva V, Lacal JC. Lucas L, et al. Oncogene. 2001 Mar 1;20(9):1110-7. doi: 10.1038/sj.onc.1204216. Oncogene. 2001. PMID: 11314048

6

The Ras family of GTPases in cancer cell invasion.

Hernández-Alcoceba R, del Peso L, Lacal JC. Hernández-Alcoceba R, et al. Cell Mol Life Sci. 2000 Jan 20;57(1):65-76. doi: 10.1007/s000180050499. Cell Mol Life Sci. 2000. PMID: 10949581 Free PMC article. Review.

7

Rho proteins induce metastatic properties in vivo.

del Peso L, Hernández-Alcoceba R, Embade N, Carnero A, Esteve P, Paje C, Lacal JC. del Peso L, et al. Oncogene. 1997 Dec 18;15(25):3047-57. doi: 10.1038/sj.onc.1201499. Oncogene. 1997. PMID: 9444953

8

Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas.

Cuevas Y, Hernández-Alcoceba R, Aragones J, Naranjo-Suárez S, Castellanos MC, Esteban MA, Martín-Puig S, Landazuri MO, del Peso L. Cuevas Y, et al. Cancer Res. 2003 Oct 15;63(20):6877-84. Cancer Res. 2003. PMID: 14583486

9

Optimization of the Tet-on system to regulate interleukin 12 expression in the liver for the treatment of hepatic tumors.

Zabala M, Wang L, Hernandez-Alcoceba R, Hillen W, Qian C, Prieto J, Kramer MG. Zabala M, et al. Cancer Res. 2004 Apr 15;64(8):2799-804. doi: 10.1158/0008-5472.can-03-3061. Cancer Res. 2004. PMID: 15087396

10

Evaluation of a new dual-specificity promoter for selective induction of apoptosis in breast cancer cells.

Hernandez-Alcoceba R, Pihalja M, Nunez G, Clarke MF. Hernandez-Alcoceba R, et al. Cancer Gene Ther. 2001 Apr;8(4):298-307. doi: 10.1038/sj.cgt.7700304. Cancer Gene Ther. 2001. PMID: 11393283

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

85 results

Search Page

Filters